R&D channel feed

Am­gen posts terse up­date on PhI­II Lumakras win — but just how big?

3 years ago
Pharma

Trapped in Nas­daq’s biotech base­ment, Co­di­ak’s Doug Williams lays out a sur­vival plan: chop­ping jobs, PhII plans

3 years ago
People

In five pa­tients, Sang­amo’s Fab­ry dis­ease gene ther­a­py ap­pears to be work­ing so far

3 years ago
Cell/Gene Tx

Sanofi nabs pri­or­i­ty re­view for he­mo­phil­ia A pro­gram as phar­ma awaits FDA de­ci­sion

3 years ago
FDA+

Two years af­ter PhII set­back, Jounce's lead I/O drug flops again de­spite bio­mark­er ap­proach

3 years ago

#ESC22: In re­turn to ‘big chron­ic dis­eases,’ Eu­rope’s car­dio con­fab show­cas­es mixed bag of da­ta drops

3 years ago
People

Four years and $145M+ lat­er, No­vo Nordisk hands back the rights to hor­mone growth de­fi­cien­cy test

3 years ago

Af­ter years of fail­ures, the hunt for a new type of Parkin­son’s drug is on

3 years ago
In Focus

#ESC22: Bay­er's chron­ic kid­ney dis­ease drug miss­es the mark on low­er­ing car­dio­vas­cu­lar death

3 years ago
Pharma

#ESC22: Cin­Cor CMO’s 17-year jour­ney in bring­ing a new hy­per­ten­sion drug to mar­ket con­tin­ues

3 years ago

#ESC22: BMS-J&J’s mil­vex­i­an miss­es com­pos­ite end­point, but duo to push drug for­ward with signs of sec­ondary stroke pre­ven­tion and ‘flat bleed­ing curve’

3 years ago
Pharma

#ESC22: Bay­er's fac­tor XIa in­hibitor miss­es ef­fi­ca­cy marks in 2 PhII stud­ies but com­pa­ny dives straight in­to PhI­II

3 years ago
Pharma

#ESC22: ‘Anx­ious for more ev­i­dence’: As­traZeneca touts DE­LIV­ER da­ta in bid to ex­pand Farx­i­ga’s heart fail­ure la­bel 

3 years ago
Pharma

With two new ex­pen­sive gene ther­a­py ap­provals, out­comes-based pric­ing deals grab the spot­light again

3 years ago
Pharma

Up­dat­ed: Mod­er­na sues Pfiz­er and BioN­Tech for in­fring­ing on mR­NA vac­cine patents used in block­buster Covid shots

3 years ago
Law

Coin flip: Top an­a­lyst gives Amy­lyx ALS drug a 50% chance at ap­proval as rare sec­ond ad­comm ap­proach­es

3 years ago
FDA+

#ESC22: 89bio heads to­ward PhI­II in se­vere hy­per­triglyc­eridemia, a field left be­hind by Pfiz­er ear­li­er this year 

3 years ago

J&J and Ab­b­Vie's block­buster BTK in­hibitor scoops a pe­di­atric in­di­ca­tion in graft-ver­sus-host dis­ease

3 years ago

Re­searchers inch clos­er in ef­fec­tive­ly (and non-tox­i­cal­ly) mar­ry­ing CRISPR and CAR-T

3 years ago

Armed with $100M grant, El­e­vate­Bio looks to cre­ate bio­man­u­fac­tur­ing cen­ter with the Uni­ver­si­ty of Pitts­burgh

3 years ago
Cell/Gene Tx
Manufacturing

French pen­ny stock will no longer knock on FDA door for ap­proval in a cer­tain type of blood can­cer

3 years ago
FDA+

Pfiz­er heads to the FDA with an ear­ly lead over ri­vals in the $10B RSV vac­cine mar­ket

3 years ago

Fac­ing fears of neu­ronal dam­age, No­var­tis slams brakes on Hunt­ing­ton's tri­al

3 years ago

Fo­cus­ing on cut­ting down sup­ply is­sues, ra­di­oli­gand biotech Ad­van­Cell rais­es $12M

3 years ago
First page Previous page 121122123124125126127 Next page Last page
A service from the Financial Times